David S. Ettinger, MD, FACP, FCCP
Dr. David S. Ettinger is the Alex Grass Professor in Oncology at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He is also a Professor of Medicine, Otolaryngology, Head and Neck Surgery, Gynecology and Obstetrics, and Radiation Oncology and Molecular Radiation Sciences.
Dr. Ettinger’s research interests are in new drug development and innovative multidisciplinary treatment strategies in lung cancer and sarcomas. He is also interested in improving supportive care measures associated with cancer and its treatment. Dr. Ettinger has been the author or co-author of more than 200 articles and serves as an editor for Current Treatment Options in Oncology. Dr. Ettinger is a member of the board of directors of the National Comprehensive Cancer Network® (NCCN®) as well as a member of the NCCN® ORP Investigator Steering Committee. In addition, he has been chairperson of the NCCN® non–small cell lung cancer practice guidelines panel, antiemetic practice guidelines panel, and occult primary tumor practice guidelines panel, malignant pleural mesothelioma practice guidelines panel, and thymomas and thymic carcinomas practice guidelines panel.
Dr. Ettinger earned an MD degree from the University of Louisville, School of Medicine in Kentucky. He completed a medical internship and residency at the Albany Medical Center in New York and Mayo Clinic in Rochester, Minnesota, respectively. He completed a fellowship in medical oncology at Johns Hopkins.
Jeffrey Crawford, MD
Jeffrey Crawford, MD, is George Barth Geller Professor for Research in Cancer at Duke University Medical Center and Co-Director of the Solid Tumor Therapeutics Program and Associate Director of Clinical Research (thoracic oncology) in the Duke Cancer Institute in Durham, North Carolina. Dr. Crawford is Principal Investigator for the National Clinical Trials Network Lead Academic Site Grant at Duke Cancer Institute.
Dr. Crawford’s research interests include new treatment approaches to lung cancer, supportive care therapies, and clinical trials of hematopoietic growth factors, biological agents, and targeted drug development. He has written more than 180 manuscripts and chapters. He is a member of the executive committee for the Alliance, Chairperson of the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for myeloid growth factors panel, and a member of the National Comprehensive Cancer Network® Investigator Steering Committee.
He earned an MD degree from Ohio State University and completed his internship, residency, and hematology/oncology fellowship at Duke University Medical Center. He also completed a fellowship in geriatrics at the Veterans Administration Medical Center in Durham, North Carolina.
Barbara J. Gitlitz, MD
Barbara J. Gitlitz, MD, is an Associate Professor of Clinical Medicine at Keck School of Medicine at the University of Southern California in Los Angeles.
Dr. Gitlitz has written or co-written book chapters and hundreds of peer-reviewed scientific articles. She is a member of the Stand Up to Cancer Epigenetics Dream Team, focusing on novel trials to treat lung cancer with immunotherapy and therapy to awaken important genes that are “turned off” by growing lung cancers. She is the Principal investigator on a prospective study to characterize the somatic and germline genomics of lung cancer occurring in patients younger than age 40.
Dr. Gitlitz earned an MD degree from the State University of New York at Stony Brook. She completed an internship in medicine at the University of California, Los Angeles; a residency in internal medicine at Cedars-Sinai Medical Center in Los Angeles; and fellowships in hematology/oncology and translational investigation at the University of California, Los Angeles.
Fred R. Hirsch, MD, PhD
Dr. Hirsch is Endowed Chair in Lung Cancer Research and a Professor of Medicine and Pathology at the University of Colorado Cancer Center in Denver.
His research interest is lung cancer and his studies have focused on the biology, pathology, and clinical aspects of lung cancer. Dr. Hirsch has focused on translational research, especially the development and validation of biomarkers for the early detection of lung cancer and for prediction of response to new molecularly targeted therapies in lung cancer. Dr. Hirsch has written more than 300 scientific articles about lung cancer and edited 10 international books on lung cancer. He sits on several editorial boards, including Lancet Oncology and Clinical Cancer Research, and he is an Associate Editor for the Journal of Thoracic Oncology. Dr. Hirsch is the Chief Executive Officer of the International Association for the Study of Lung Cancer.
Dr. Fred R. Hirsch earned MD and PhD degrees from the University of Copenhagen in Denmark. He completed clinical training in medical oncology and pathology at various university hospitals in Denmark and was a research fellow in medical oncology at the US National Cancer Institute.
Leora Horn, MD, MSc, FRCPC
Dr. Leora Horn is an Associate Professor of Medicine and the Clinical Director of the Thoracic Oncology Research Program at Vanderbilt Ingram Cancer Center in Nashville, Tennessee. She is also the Assistant Vice Chancellor for Faculty Development at Vanderbilt University Medical Center.
Her clinical practice focuses on the care of patients with lung cancer. She is an active member of the Eastern Cooperative Oncology Group, International Association for the Study of Lung Cancer, and the American Society of Clinical Oncology. She has over 70 articles published in The New England Journal of Medicine, Nature Medicine, and the Journal of Clinical Oncology. She has a focus on clinical trials with targeted therapies and immunotherapy as well as small cell lung cancer.
Dr. Horn earned an MD degree from the University of Toronto in Canada, where she also completed a residency in internal medicine and medical oncology. She completed a sub-specialty fellowship in thoracic oncology at Vanderbilt University.
Benjamin Levy, MD
Dr. Benjamin Levy is the Medical Director of Thoracic Medical Oncology for Mount Sinai Health Systems and the Associate Medical Director of the Cancer Clinical Trials Office for Mount Sinai Hospital.
His main focus is the comprehensive clinical care and research development for patients with thoracic malignancies, with particular emphasis on non–small cell lung cancer. In addition to his clinical and research duties, Dr. Levy serves as Associate Editor for the ASCO University Committee, where he helps develop educational web-based content for oncologists across the country. Dr Levy actively publishes in peer-reviewed journals including the Journal of the National Comprehensive Cancer Network, Journal of Oncology Practice, and the Journal of Thoracic Oncology. He serves as an ad hoc reviewer for journals including Clinical Lung Cancer and The Oncologist.
Dr. Levy earned an MD degree from the Medical College of Georgia in Augusta; completed an internal medicine residency at Georgetown University Hospital in Washington, DC; and completed a fellowship in hematology/oncology at New York Presbyterian–Weill Cornell in New York City.
Roman Perez-Soler, MD
Dr. Roman Perez-Soler is Chairman of the Department of Oncology at Montefiore Medical Center, Chief of the Division of Medical Oncology in the Department of Medicine at Albert Einstein College of Medicine, and Deputy Director of the Albert Einstein Cancer Center.
His clinical and translational research focuses on novel approaches for the treatment for lung cancer and has been funded by the National Institutes of Health. Dr. Perez-Soler is currently RO1 funded for the development of inhaled demethylating therapies for lung cancer, and he is Principal Investigator of the National Cancer Institute–funded K12 Paul Calabresi Award for Clinical Oncology at Albert Einstein Cancer Center, a program that has trained 13 young clinical investigators. He currently serves on the National Cancer Institute’s Board of Scientific Counselors for Clinical Sciences and Epidemiology. Dr. Perez-Soler holds 17 patents and has written more 200 articles and book chapters.
Dr. Perez-Soler earned an MD degree from the Universidad Autonoma in Barcelona, Spain, and completed a residency at the Universidad de Barcelona and a fellowship in medical oncology at the MD Anderson Cancer Center in Houston, Texas.
David Spigel, MD
Dr. David Spigel is Chief Scientific Officer at Sarah Cannon Research Institute, where he oversees all scientific aspects of the clinical trial program, and, as Director of the Lung Cancer Research Program, he works with research physician leaders to ensure the best new agents and studies are available to patients with cancer. He is board certified in medical oncology and is a Medical Oncologist at Tennessee Oncology.
Dr. Spigel earned an MD degree from The University of Tennessee in Memphis. He completed an internal medicine and chief residency at Indiana University Medical Center in Indianapolis and a fellowship in hematology and oncology at the Dana-Farber Cancer Institute in Boston.